SCHEMBL14514

SCHEMBL14514

CN(CCCNCc1ccc(-n2cc3cc(-c4ccc(C(=O)NC5CCNCC5)cc4)[nH]c3nc2=O)cc1)C(=N)N

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.37
CHUK O15111 2/20 0.35
INSR P06213 2/20 0.35
MAPK8 P45983 2/20 0.35
CAMKK2 Q96RR4 2/20 0.35
DHODH Q02127 1/20 0.34
KHK P50053 4/20 0.34
IKBKB O14920 1/20 0.34
SUV39H2 Q9H5I1 2/20 0.33
HDAC4 P56524 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
KDM1A O60341 1/20 0.32
MAPK14 Q16539 2/20 0.32
SMYD3 Q9H7B4 3/20 0.32
PPARG P37231 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14232 0.89 RIPK1 (0.39) RIPK1CHUKINSRMAPK8CAMKK2
SCHEMBL14512 0.88 RIPK1 (0.41) RIPK1DHODHKHKIKBKBSUV39H2
SCHEMBL13804 0.84 RIPK1 (0.37) RIPK1CHUKINSRMAPK8CAMKK2
SCHEMBL14330 0.83 RIPK1 (0.38) RIPK1DHODHKHKIKBKBSUV39H2
SCHEMBL14513 0.82 RIPK1 (0.46) RIPK1DHODHKHKIKBKBSUV39H2
SCHEMBL14057 0.81 RIPK1 (0.36) RIPK1CHUKINSRMAPK8CAMKK2
SCHEMBL13865 0.81 RIPK1 (0.40) RIPK1CHUKINSRMAPK8CAMKK2
SCHEMBL14436 0.80 RIPK1 (0.39) RIPK1DHODHKHKIKBKBSUV39H2
SCHEMBL14026 0.77 CCNA2 (0.35) RIPK1DHODHKHKKDM1A
SCHEMBL13856 0.76 KLKB1 (0.38) KHKIKBKBSMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT RIPK1 2895/4885CHUK 2953/4885INSR 4144/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT RIPK1 2895/4885CHUK 2953/4885INSR 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.